Therapeutic antibodies

An isolated canine antibody or antigen-binding portion thereof which binds to one of the following epitopes of the extracellular domain of canine PD-1:

• i) an epitope comprising T76, Q83, E84, L128, P129, P130 according to SEQ ID NO:
• 2
• ii) an epitope comprising D58, D61, N74, T76, Y127 according to SEQ ID NO:
• 2 wherein the epitope is determined using an epitope mapping technique.

An isolated canine antibody or antigen-binding portion thereof which binds canine PD-1 wherein said antibody comprises

• a) an HC CDR1 sequence comprising SEQ ID NO:
• 17 or an amino acid sequence which has 1, 2, 3, 4, or 5 amino acid differences compared to SEQ ID NO:
• 17 and an HC CDR2 sequence comprising SEQ ID NO:
• 18 or an amino acid sequence which has 1, 2, 3, 4, 5, or 6 amino acid differences compared to SEQ ID NO:
• 18 and an HC CDR3 sequence comprising SEQ ID NO:
• 19 or an amino acid sequence which has 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acid differences compared to SEQ ID NO:
• 19 and an LC CDR1 sequence comprising SEQ ID NO:
• 20 or an amino acid sequence which has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 amino acid differences compared to SEQ ID NO:
• 20 and an LC CDR2 sequence comprising SEQ ID NO:
• 21 or an amino acid sequence which has 1, 2, 3, 4, or 5 amino acid differences compared to SEQ ID NO:
• 21 and an LC CDR3 sequence comprising SEQ ID NO:
• 22 or an amino acid sequence which has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid differences compared to SEQ ID NO:
• 22;
• b) an HC CDR1 sequence comprising SEQ ID NO:
• 207 or an amino acid sequence which has 1, or 2 amino acid differences compared to SEQ ID NO:
• 207 and an HC CDR2 sequence comprising SEQ ID NO:
• 208 or an amino acid sequence which has 1, 2, 3, 4, or 5 amino acid differences compared to SEQ ID NO:
• 208 and an HC CDR3 sequence comprising SEQ ID NO:
• 209 or an amino acid sequence which has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 amino acid differences compared to SEQ ID NO:
• 209 and an LC CDR1 sequence comprising SEQ ID NO:
• 210 or an amino acid sequence which has 1, 2 or 3 amino acid differences compared to SEQ ID NO:
• 210 and an LC CDR2 sequence comprising SEQ ID NO:
• 211 or an amino acid sequence which has 1 or 2 amino acid differences compared to SEQ ID NO:
• 211 and an LC CDR3 sequence comprising SEQ ID NO:
• 212 or an amino acid sequence which has 1, 2, 3, or 4 amino acid differences compared to SEQ ID NO:
• 212;
• or
• c) an HC CDR1 sequence comprising SEQ ID NO:
• 97 or an amino acid sequence which has 1, 2, or 3 amino acid differences compared to SEQ ID NO:
• 97 and an HC CDR2 sequence comprising SEQ ID NO:
• 98 or an amino acid sequence which has 1, 2, 3, or 4 amino acid differences compared to SEQ ID NO:
• 98 and an HC CDR3 sequence comprising SEQ ID NO:
• 99 or an amino acid sequence which has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acid differences compared to SEQ ID NO:
• 99 and an LC CDR1 sequence comprising SEQ ID NO:
• 100 or an amino acid sequence which has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid differences compared to SEQ ID NO:
• 100 and an LC CDR2 sequence comprising SEQ ID NO:
• 101 or an amino acid sequence which has 1, 2, 3, 4, or 5 amino acid differences compared to SEQ ID NO:
• 101 and an LC CDR3 sequence comprising SEQ ID NO:
• 102 or an amino acid sequence which has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid differences compared to SEQ ID NO:
• 102.